The College of American Pathologists (CAP), the AMERICAN SOCIETY FOR CLINICAL PATHOLOGY (ASCP), and the AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) collaborated to develop a clinical practice guideline that addresses appropriate testing of HER2/neu status in patients with gastric and gastroesophageal (GEA) cancers.
Titled “CAP-ASCP-ASCO HER2 TESTING AND CLINICAL DECISION MAKING IN GASTROESOPHAGEAL ADENOCARCINOMA GUIDELINE,” this evidence-based guidance is now available as an early online release published in Archives of Pathology & Laboratory Medicine, American Journal of Clinical Pathology, and the Journal of Clinical Oncology.
The overarching questions that the guideline development panel of experts addressed were:
- What is the optimal testing algorithm to assess HER2 status in patients with GEA?
- What strategies can help ensure optimal performance, interpretation, and reporting of established assays in patients with GEA?
Descarregar guideline aqui
1 – Angela N. Bartley, Mary Kay Washington, Christina B. Ventura, Nofisat Ismaila, Carol Colasacco, Al B. Benson III, Alfredo Carrato, Margaret L. Gulley, Dhanpat Jain, Sanjay Kakar, Helen J. Mackay, Catherine Streutker, Laura Tang, Megan Troxell, and Jaffer A. Ajani(2016) HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Archives of Pathology & Laboratory Medicine: December 2016, Vol. 140, No. 12, pp. 1345-1363.